An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers

Yamauchi, Junji; Araya, Natsumi; Yagishita, Naoko; Sato, Tomoo; Yamano, Yoshihisa

doi:10.1016/j.pharmthera.2020.107669

Cited by 39 publications

(49 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to ATLL, HTLV-1 infection is also etiologically associated with several autoimmune-like inflammatory diseases, the most important being HAM/TSP, which is a demyelinating disease involving primarily the spinal cord and develops in about 4% of HTLV-1 carriers [ 93 , 94 ]. It is characterized by chronic progressive spasticity and weakness, bladder disfunction, and increasing sensory deficits of the lower extremities [ 93 , 94 ]. In contrast to ATLL, HAM/TSP tends to develop in HTLV-1 carriers infected in adulthood through sexual transmission or contaminated blood [ 93 , 94 ].…”

Section: Htlv-1 Atll and Ham/tspmentioning

confidence: 99%

“…It is characterized by chronic progressive spasticity and weakness, bladder disfunction, and increasing sensory deficits of the lower extremities [ 93 , 94 ]. In contrast to ATLL, HAM/TSP tends to develop in HTLV-1 carriers infected in adulthood through sexual transmission or contaminated blood [ 93 , 94 ]. Corticosteroids constitute the current major treatments of HAM/TSP but only with partial effectiveness [ 94 ].…”

Section: Htlv-1 Atll and Ham/tspmentioning

confidence: 99%

See 1 more Smart Citation

CCR4 as a Therapeutic Target for Cancer Immunotherapy

Yoshie

2021

Cancers

View full text Add to dashboard Cite

CCR4 is a chemokine receptor mainly expressed by T cells. It is the receptor for two CC chemokine ligands, CCL17 and CCL22. Originally, the expression of CCR4 was described as highly selective for helper T type 2 (Th2) cells. Later, its expression was extended to other T cell subsets such as regulatory T (Treg) cells and Th17 cells. CCR4 has long been regarded as a potential therapeutic target for allergic diseases such as atopic dermatitis and bronchial asthma. Furthermore, the findings showing that CCR4 is strongly expressed by T cell malignancies such as adult T cell leukemia/lymphoma (ATLL) and cutaneous T cell lymphomas (CTCLs) have led to the development and clinical application of the fully humanized and glyco-engineered monoclonal anti-CCR4 Mogamulizumab in refractory/relapsed ATLL and CTCLs with remarkable successes. However, Mogamulizumab often induces severe adverse events in the skin possibly because of its efficient depletion of Treg cells. In particular, treatment with Mogamulizumab prior to allogenic hematopoietic stem cell transplantation (allo-HSCT), the only curative option of these T cell malignancies, often leads to severe glucocorticoid-refractory graft-versus-host diseases. The efficient depletion of Treg cells by Mogamulizumab has also led to its clinical trials in advanced solid tumors singly or in combination with immune checkpoint inhibitors. The main focus of this review is CCR4; its expression on normal and malignant T cells and its significance as a therapeutic target in cancer immunotherapy.

show abstract

Section: Htlv-1 Atll and Ham/tspmentioning

confidence: 99%

Section: Htlv-1 Atll and Ham/tspmentioning

confidence: 99%

CCR4 as a Therapeutic Target for Cancer Immunotherapy

Yoshie

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Proviral load in cerebrospinal fluid is important to define the progression of HAM since HTLV-1 infected cells in the central nervous system accelerate the local inflammatory process 26,[85][86][87] . However, other prognostic value markers should be evaluated to identify people at higher risk of illness [88][89][90] .…”

Section: Epidemiological Aspectsmentioning

confidence: 99%

Brazilian Protocol for Sexually Transmitted Infections 2020: human T-cell lymphotropic virus (HTLV) infection

Rosadas

Brites

Arakaki-Sanchéz

et al. 2021

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

This article addresses the Human T-lymphotropic virus (HTLV). This subject comprises the Clinical Protocol and Therapeutic Guidelines for Comprehensive Care for People with Sexually Transmitted Infections, published by the Brazilian Ministry of Health. HTLV-1/2 infection is a public health problem globally, and Brazil has the largest number of individuals living with the virus. HTLV-1 causes several clinical manifestations of neoplasm (adult T-cell leukemia/lymphoma) and inflammatory nature, such as HTLV-1-associated myelopathy and other manifestations such as uveitis, arthritis, and infective dermatitis. These pathologies have high morbidity and mortality and negatively impact the quality of life of infected individuals. This review includes relevant information for health authorities professionals regarding viral transmission, diagnosis, treatment, and monitoring of individuals living with HTLV-1 and 2 in Brazil.

show abstract

“…26, [85][86][87] Sin embargo, se deben evaluar otros marcadores de valor pronóstico, para identificar a las personas con mayor riesgo de la enfermedad. [88][89][90] Leucemia/linfoma de células T del adulto La neoplasia de células T periféricas causada por HTLV-1 se presenta con leucocitosis, se caracteriza por la presencia de linfocitos anormales (células florales -flower cells) y, clínicamente, por linfadenopatías, lesiones cutáneas, disfunción multiorgánica resultante de la invasión de células neoplásicas, además de la presencia de infecciones oportunistas. Son característicos los niveles elevados de la enzima lactato deshidrogenasa y la hipercalcemia.…”

Section: Mielopatía Asociada Al Htlv-1unclassified

Protocolo Brasileiro para Infecções Sexualmente Transmissíveis 2020: infecção pelo vírus linfotrópico de células T humanas (HTLV)

Rosadas

Brites

Arakaki-Sanchéz

et al. 2021

Epidemiol. Serv. Saúde

View full text Add to dashboard Cite

Resumo O artigo aborda a infecção pelo vírus linfotrópico de células T humanas (human T lymphotropic virus, HTLV), tema contemplado no Protocolo Clínico e Diretrizes Terapêuticas para Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis, publicado pelo Ministério da Saúde do Brasil. A infecção pelo HTLV-1/2 é um problema de saúde pública mundial, sendo o Brasil o país a referir o maior número de indivíduos convivendo com o vírus. O HTLV-1 causa diversas manifestações clínicas, de natureza neoplásica, como a leucemia/linfoma de células T do adulto, e de natureza inflamatória, a exemplo da mielopatia associada ao HTLV-1 e outras alterações, como uveíte, artrite e dermatite infecciosa. Estas patologias apresentam elevada morbimortalidade e impactam negativamente a qualidade de vida dos indivíduos infectados. A presente revisão inclui informações relevantes para gestores e profissionais de saúde sobre os mecanismos de transmissão viral, diagnóstico, tratamento e acompanhamento de indivíduos vivendo com o HTLV-1/2 no Brasil.

show abstract

An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers

Cited by 39 publications

References 120 publications

CCR4 as a Therapeutic Target for Cancer Immunotherapy

CCR4 as a Therapeutic Target for Cancer Immunotherapy

Brazilian Protocol for Sexually Transmitted Infections 2020: human T-cell lymphotropic virus (HTLV) infection

Protocolo Brasileiro para Infecções Sexualmente Transmissíveis 2020: infecção pelo vírus linfotrópico de células T humanas (HTLV)

Contact Info

Product

Resources

About